Skip to main content

Table 2 Patient characteristics of “TNFi success” and “failing TNFi” cohorts

From: Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

 AllNorth AmericaLatAmEU5APACT&ME
GroupTNFi Success
(n = 1275)
Failing TNFi
(n = 232)
TNFi Success
(n = 270)
Failing TNFi
(n = 56)
TNFi Success
(n = 73)
Failing TNFi(n = 15)TNFi Success
(n = 733)
Failing TNFi
(n = 103)
TNFi Success
(n = 112)
Failing TNFi
(n = 44)
TNFi Success
(n = 87)
Failing TNFi
(n = 14)
Age, years
 Median43.045.045.047.041.045.044.049.040.036.538.034.0
 Mean (SD)43.8 (12.1)45.7 (13.2)45.5 (13.4)47.8 (12.0)42.5 (12.0)44.8 (6.3)44.6 (11.8)48.8 (13.8)40.6 (12.4)39.3 (13.5)37.8 (6.9)35.9 (4.7)
P0.05160.19960.09560.00350.53100.2808
Male, n (%)1009 (79.1)165 (71.1)220 (81.5)42 (75.0)50 (68.5)9 (60.0)582 (79.4)66 (64.1)90 (80.4)36 (81.8)67 (77.0)12 (85.7)
P0.00970.27080.55540.000910.7287
BMI, kg/m2
 Median25.325.225.927.025.625.025.225.623.422.925.625.7
 Mean (SD)25.7 (3.8)26.0 (4.7)26.5 (4.1)27.8 (4.9)25.9 (3.2)25.2 (5.0)25.5 (3.4)26.2 (4.5)23.8 (4.3)23.4 (4.0)26.8 (4.7)26.5 (4.0)
P0.85630.04180.35700.28090.46380.9881
Current Smoker
 n, %381 (29.9)81 (34.9)37 (13.7)17 (30.4)7 (9.6)2 (13.3)252 (34.4)38 (36.9)29 (25.9)17 (38.6)56 (64.4)7 (50.0)
P0.14120.00490.64710.65860.12350.3761
Time since symptom onset (years)
 n111019623843731561186103388514
 Median7.08.08.010.05.03.09.010.08.05.02.32.0
 Mean (SD)10.4 (9.2)11.7 (11.2)12.0 (10.8)11.6 (9.1)8.9 (9.7)8.3 (10.9)10.8 (8.8)14.5 (12.6)10.8 (8.4)9.9 (10.4)3.0 (2.1)3.3 (2.7)
P0.60810.70410.29770.05540.19780.8485
Time since diagnosis (years)
 n117020925351721565991103388314
 Median5.05.05.05.03.02.05.06.05.03.01.21.0
 Mean (SD)7.2 (7.2)8.4 (9.6)7.9 (8.1)9.0 (9.3)5.9 (6.4)6.6 (10.5)7.8 (7.0)10 (10.3)7.2 (6.7)6.7 (8.5)1.7 (1.8)2.1 (2.2)
P0.74890.26470.30550.19460.08860.7456
HLA-B27 + ve
 n919145204356312542696522457
 n, %809 (88.0)129 (89.0)177 (86.8)32 (91.4)57 (90.5)12 (100.0)484 (89.3)59 (85.5)55 (84.6)20 (90.9)36 (80.0)6 (85.7)
P0.89000.58610.58110.31590.72241
Current AS symptoms
 n1275232270567315733103112448714
 Median1.02.02.02.52.01.01.02.01.02.01.02.0
 Mean (SD)1.8 (1.4)2.5 (1.7)2.1 (1.7)3.1 (2.2)1.9 (1.4)1.7 (1.2)1.6 (1.3)2.4 (1.6)1.8 (1.6)2.3 (1.4)1.5 (1.5)1.9 (1.4)
P< 0.00010.00030.6424< 0.00010.02030.2567
ESR, mm/hr (within 3 months)
 n780143148364374385779297214
 Median12.020.014.031.510.012.012.021.010.015.020.032.0
 Mean (SD)15.1 (11.8)24.9 (19.3)17.8 (12.8)27.4 (19.0)11.5 (7.8)11.1 (8.5)13.8 (11.6)22.5 (16.3)13.0 (12.0)28.4 (26.8)22.0 (8.8)28.3 (13.7)
P< 0.00010.00780.9551< 0.00010.00350.1976
CRP, mg/l (within 3 months)
 n718124116243544255474286814
 Median2.55.01.63.32.01.03.06.01.13.02.64.9
 Mean (SD)4.5 (6.0)7.2 (9.0)4.6 (8.2)7.7 (9.5)3.2 (4.0)0.8 (0.5)4.7 (5.1)9.8 (11.2)3.7 (7.5)3.6 (3.3)4.2 (5.9)5.0 (0.9)
P< 0.00010.01670.1117< 0.00010.31600.0042
  1. Patients were deemed to be failing TNFi after at least 3 months if disease severity had worsened or remained severe, disease activity was unstable or deteroriating, disease was not considered by physician to be controlled, nor treatment a success. Patients not considered to be failing TNFi were considered to be “TNFi success”
  2. Abbreviations: APAC Asia Pacific region, AS ankylosing spondylitis, BMI body mass index, CRP c-reactive protein, ESR erthyrocyte sedimentation rate, EU5 European Union 5, HLA-B27 human leukocyte antigen B27, LatAm Latin America, T&ME Turkey and Middle East, SD standard deviation